Xencor (XNCR) Osake Kurssi

Xencor Inc is primarily active in the biotechnology industry.

The main competitors of Xencor Inc in the market include big pharmaceutical companies such as Amgen, Johnson & Johnson, and Roche. These companies are also engaged in the development and commercialization of biopharmaceutical products in various therapeutic areas. Xencor Inc, a leading clinical-stage biopharmaceutical company, focuses on discovering and developing engineered monoclonal antibodies for treating severe and life-threatening diseases.

Xencor Inc, founded in 1997, is a renowned biopharmaceutical company based in Monrovia, California. With a focus on developing monoclonal antibody therapeutics, Xencor has become a leader in the field of immuno-oncology and autoimmune diseases. The company employs its proprietary XmAb® technology platform, allowing for enhanced antibody engineering and development. Xencor has established numerous strategic partnerships with renowned pharmaceutical companies, leveraging its expertise to create innovative treatments. Recognized for its rigorous scientific approach and commitment to pioneering medicine, Xencor continues to advance its pipeline for potential therapies, aiming to improve patient outcomes in various disease areas.

Xencor Inc, a leading biopharmaceutical company, has achieved several significant milestones since its inception. The company successfully advanced its proprietary XmAb® technology, bringing innovative antibody therapeutics to market. Xencor Inc also forged strategic collaborations with renowned pharmaceutical companies, facilitating the development and commercialization of novel therapies. The company's dedication to research and development resulted in the initiation of multiple clinical trials, highlighting its commitment to addressing unmet medical needs. Xencor Inc's milestones include securing regulatory approvals and advancing therapeutic candidates across a range of diseases, solidifying its position in the biopharmaceutical industry. With its impactful achievements, Xencor Inc continues to drive innovation and improve patient outcomes globally.

Xencor Inc is primarily present in the United States.

Xencor Inc represents values and a corporate philosophy focused on advancing breakthrough medicines for patients. With a commitment to innovation and cutting-edge technology, Xencor is dedicated to transforming the treatment of serious diseases. The company's core values encompass scientific excellence, integrity, collaboration, and resilience. By leveraging its proprietary XmAb® technology, Xencor aims to create next-generation antibody therapeutics that have the potential to deliver improved outcomes for patients. With a robust pipeline and strong research capabilities, Xencor strives to make a meaningful impact in the field of biotechnology, driving advancements in human health.

Analyytikot asettavat tällä hetkellä Xencor-osakkeelle keskimääräisen tavoitehinnan 30,33 USD (mediaani: 27,00 USD), mikä merkitsee +25,0 % viimeisimpään hintaan verrattuna. Konsensus perustuu 20 analyytikkoarvioon.

Xencor Analyytikkojen kursstavoitteet 2026

20 analyytikkoa arvioi tällä hetkellä Xencor-osaketta: 17 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat Xencor-yhtiöltä 143,22 M USD liikevaihtoa ja −2,96 USD osakekohtaista tulosta.

Xencor Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla Xencor-osake noteerataan hintaan 21,66 EUR (24,26 USD).

Xencor-osake (XNCR) on listattuna 5 pörssissä, muun muassa: NASDAQ (XNCR), SIX (Zürich) (XE9.SW), Frankfurt (XE9.F), München (XE9.MU), Düsseldorf (XE9.DU).

Xencor Inc is a biopharmaceutical company specializing in the development of protein-based therapeutics and antibodies for the treatment of cancer and autoimmune diseases. The company follows an innovative business model based on proprietary protein engineering technologies. Xencor's product range includes a wide variety of therapeutics and antibodies specifically tailored to the needs of patients with serious diseases. The company's key products include: 1. XmAb Program - A family of antibody platforms based on Xencor's proprietary protein design technology. This platform allows researchers to develop antibodies with improved efficacy and safety. The program has the potential to target a wide range of molecules and therefore serve a broad spectrum of indications. 2. Bispecific Platform - A technology that enables the development of antibodies capable of simultaneously binding to two different target molecules on the surface of cancer cells or immune cells. These bispecifics allow for targeted destruction of cancer cells or activation of immune cells and can therefore offer unique therapeutic possibilities for cancer patients. 3. Xtend-Fc Technology - A platform based on the extension of the half-life of biological drugs. By extending the half-life of therapeutics, they can be administered less frequently, improving patients' quality of life and treatment adherence. The company operates two main business areas: in-house research and partnerships. In the field of in-house research, Xencor focuses on the development of innovative therapeutics that are either marketed on their own or go into product development in partnership with leading pharmaceutical companies. Xencor has an impressive list of collaboration partners where the company provides its technology platforms to jointly develop innovative therapeutics. Key partnerships include Novartis, Merck, Amgen, and Morphosys. Another source of revenue for Xencor is the licensing of its technology platforms and product candidates to other pharmaceutical companies. The company has entered into several licensing agreements with international pharmaceutical and biotech companies, giving it access to new technologies and markets and enabling the global distribution of its products. Xencor Inc has a clear focus on the development of protein-based therapeutics and antibodies. The company pursues a diversified business strategy that focuses on the development of innovative products and platform technologies, as well as collaboration with industry leaders. Through this strategy, Xencor Inc is able to provide patients worldwide with access to a wide range of therapeutics aimed at optimized clinical outcomes and improved safety.

odotettu liikevaihto Xencor on 143,22 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Xencor on −219,44 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Xencor:n hinta-voitto-suhde (P/E) on tällä hetkellä −8,21. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Xencor-osakkeen arvostusta.

Xencor:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,58. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Xencor-osakkeen arvostuskennuslukuna.

Xencor:n Eulpool-laatuscore on 2/10.

Xencor:n ISIN on US98401F1057. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Xencor:n WKN on A1W96L. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Xencor:n ticker on XNCR. Tämä pörssinoteeraus käytetään Xencor-osakkeiden kauppaan pörssissä.